dopamine D1 antagonist

Ecopipam Reduced Relapse Risk in Pediatric Tourette Syndrome Without Metabolic or Extrapyramidal Signal in a Phase 3 Randomized Withdrawal Trial

In a phase 3 randomized withdrawal trial, ecopipam maintained tic improvement in pediatric Tourette syndrome over 24 weeks and showed a generally favorable safety profile without clinically meaningful weight, metabolic, or drug-induced move